Theravance Biopharma (NASDAQ:TBPH) Raised to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Theravance Biopharma (NASDAQ:TBPH) from a hold rating to a buy rating in a report issued on Saturday.

TBPH has been the topic of a number of other reports. Jones Trading upgraded shares of Theravance Biopharma to a “strong-buy” rating and set a $24.00 target price on the stock in a research note on Tuesday, June 17th. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Theravance Biopharma in a research report on Tuesday, February 25th. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $14.50.

Theravance Biopharma Trading Down 0.6%

Shares of NASDAQ:TBPH opened at $10.57 on Friday. The company has a market capitalization of $528.50 million, a price-to-earnings ratio of -8.96 and a beta of -0.09. The firm’s 50-day moving average is $9.82 and its 200 day moving average is $9.48. Theravance Biopharma has a 12 month low of $7.44 and a 12 month high of $11.82.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.16). The business had revenue of $15.39 million during the quarter, compared to the consensus estimate of $28.08 million. Theravance Biopharma had a negative net margin of 89.38% and a negative return on equity of 32.37%. As a group, equities analysts forecast that Theravance Biopharma will post -1.09 EPS for the current fiscal year.

Insider Activity at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the firm’s stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the sale, the senior vice president now owns 370,038 shares of the company’s stock, valued at approximately $3,330,342. This trade represents a 1.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Theravance Biopharma

Several institutional investors have recently added to or reduced their stakes in TBPH. Rhumbline Advisers lifted its stake in shares of Theravance Biopharma by 3.8% during the first quarter. Rhumbline Advisers now owns 62,254 shares of the biopharmaceutical company’s stock worth $556,000 after buying an additional 2,293 shares during the period. Acadian Asset Management LLC lifted its holdings in shares of Theravance Biopharma by 121,993.7% during the first quarter. Acadian Asset Management LLC now owns 174,594 shares of the biopharmaceutical company’s stock worth $1,554,000 after purchasing an additional 174,451 shares during the period. Jane Street Group LLC lifted its holdings in shares of Theravance Biopharma by 169.2% during the first quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company’s stock worth $1,258,000 after purchasing an additional 88,540 shares during the period. Park West Asset Management LLC lifted its holdings in shares of Theravance Biopharma by 0.6% during the first quarter. Park West Asset Management LLC now owns 1,804,244 shares of the biopharmaceutical company’s stock worth $16,112,000 after purchasing an additional 11,256 shares during the period. Finally, AQR Capital Management LLC acquired a new stake in Theravance Biopharma during the 1st quarter valued at approximately $101,000. Institutional investors and hedge funds own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.